Introduction to Cutaneous Melanoma
Among all skin cancers, melanoma is the most aggressive, with increasing incidence worldwide and a high potential of metastatic spread. Survival rates in the metastatic stage are poor and therapy is limited. While many aspects of the etiology of melanoma are not yet clearly understood, several risk factors have been described and will be discussed later in this chapter. In the past, therapy options remained limited and were only modestly effective in advanced disease. In recent years, research on melanoma has been progressing rapidly, and genetic and immunologic factors associated with melanoma development and progression have been identified, offering avenues for new therapeutic strategies, including immunomodulating and targeted agents.
KeywordsSkin Cancer Basal Cell Carcinoma Cutaneous Melanoma Actinic Keratosis TERT Promoter Mutation
Unable to display preview. Download preview PDF.
- 1.Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41:28-44.Google Scholar
- 2.Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45-60.Google Scholar
- 3.Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040-2059.Google Scholar
- 4.Cancer Facts & Figures 2010. American Cancer Society. www.cancer.org/downloads/STT/Cancer_Facts_and_Figures_2010.pdf. Accessed June 20, 2013.
- 5.Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012;87:328-334.Google Scholar
- 6.GLOBOCAN 2008 (IARC) Section of Cancer Information. FAST STATS. World. globocan.iarc.fr/factsheets/populations/factsheet.asp?uno = 900. Accessed June 20, 2013.Google Scholar
- 7.Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2007;60:32-40.Google Scholar
- 8.Ultraviolet radiation and the INTERSUN Programme. World Health Organization. www.who.int/uv/faq/skincancer/en/index1.html. Accessed June 20, 2013.
- 9.Kaatsch P, Spix C, Katalinic A, Hentschel S. Malignes Melanom der Haut. In: Krebs in Deutschland 2007/2008. Berlin, Germany: Robert Koch-Institut; 2012.Google Scholar
- 10.Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol. 2011;65(5 suppl 1): S78.e.1-S78.e.10.Google Scholar
- 11.Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet. 2009;126:499-510.Google Scholar
- 12.Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet. 2009;18:R9-R17.Google Scholar
- 13.Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705-727.Google Scholar
- 14.National Institutes of Health summary of the Consensus Development Conference on Sunlight, Ultraviolet Radiation, and the Skin. Bethesda, Maryland, May 8-10, 1989. Consensus Development Panel. J Am Acad Dermatol. 1991;24:608-612.Google Scholar
- 15.Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959-961.Google Scholar
- 16.Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med. 1999;340:1341-1348.Google Scholar
- 17.Stierner U, Augustsson A, Rosdahl I, Suurkula M. Regional distribution of common and dysplastic naevi in relation to melanoma site and sun exposure. A case-control study. Melanoma Res. 1992;1:367-375.Google Scholar
- 18.Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick′s Dermatology in General Medicine. 5th edn. New York, NY: McGraw-Hill; 1999.Google Scholar
- 19.International Classification of Diseases for Oncology. 3rd edn (ICD-O-3). Geneva, Switzerland: World Health Organization; 2000.Google Scholar
- 20.Rhodes AR, Weinstock MA, Fitzpatrick TB, Mihm MC, Sober AJ. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA. 1987;258:3146-3154.Google Scholar
- 21.The Melanoma Genetics Consortium. www.genomel.org. Accessed June 20, 2013.
- 22.de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37.Google Scholar
- 23.Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007;13:5256-5261.Google Scholar
- 24.Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81.Google Scholar
- 25.Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012;18:27-35.Google Scholar
- 26.Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25:601-613.Google Scholar
- 27.Sullivan RJ, Flaherty KT. BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer. 2011;2011:423239.Google Scholar
- 28.Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012;18:27-35.Google Scholar
- 29.Glud M, Gniadecki R. MicroRNAs in the pathogenesis of malignant melanoma. J Eur Acad Dermatol Venereol. 2013;27:142-150.Google Scholar
- 30.Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251-263.Google Scholar
- 31.Planta MB. Sunscreen and melanoma: is our prevention message correct? J Am Board Fam Med. 2011;24:735-739.Google Scholar
- 32.Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012;66:201-211.Google Scholar